Literature DB >> 35414426

Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.

Xiaoman Hou1, Yali Zhai2, Kevin Hu3, Chia-Jen Liu2, Aaron Udager2, Celeste L Pearce4, Eric R Fearon5, Kathleen R Cho6.   

Abstract

OBJECTIVES: The "incessant ovulation" hypothesis links increased risk for tubo-ovarian high-grade serous carcinoma (HGSC) due to more ovulations and reduced risk conferred by pre-menopausal exposures like oral contraceptive use, multiparity, and breastfeeding. However, most women diagnosed with HGSC are postmenopausal, implying age is a major risk factor for HGSC. Our mouse model for HGSC, based on tamoxifen (TAM)-induced somatic inactivation of the Brca1, Trp53, Rb1, and Nf1 (BPRN) tumor suppressor genes in oviductal epithelium, recapitulates key genetic, histopathologic, and biological features of human HGSCs. We aimed to credential the model for future efforts to define biological and risk modification factors in HGSC pathogenesis.
METHODS: BPRN mice were treated with TAM to induce tumors at defined ages and parity status.
RESULTS: BPRN mice aged 9-months prior to tumor induction had markedly shorter survival than 6-8 week old mice induced to form tumors (median 46.5 weeks versus 61.5 weeks, log-rank test P = 0.0006). No significant differences in cancer phenotypes were observed between multiparous versus nulliparous BPRN mice. However, using a modified tumor model with one wild-type Nf1 allele (BPRNfl/+), nulliparous mice had more advanced tumors than multiparous mice (Mantel-Haenszel Chi-square test of association, P = 0.01).
CONCLUSIONS: Our findings show aging is associated with significantly shortened survival post tumor induction in the BRPN model and multiparity delays development and/or progression of HGSC in certain genetic contexts. The findings support relevance of our mouse model to gain mechanistic insights into how known factors exert their protective effects and to test novel approaches for HGSC prevention.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetically engineered mouse model; High-grade serous carcinoma; Incessant ovulation hypothesis; Ovarian cancer

Mesh:

Year:  2022        PMID: 35414426      PMCID: PMC9533776          DOI: 10.1016/j.ygyno.2022.03.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.304


  41 in total

1.  Poorer survival of elderly patients with ovarian cancer: a population-based study.

Authors:  P Petignat; G Fioretta; H M Verkooijen; A T Vlastos; E Rapiti; C Bouchardy; G Vlastos
Journal:  Surg Oncol       Date:  2004-12       Impact factor: 3.279

2.  The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

Authors:  Fabiola Medeiros; Michael G Muto; Yonghee Lee; Julia A Elvin; Michael J Callahan; Colleen Feltmate; Judy E Garber; Daniel W Cramer; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

3.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

4.  Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer.

Authors:  Adrianne Mallen; Sarah Todd; Sharon E Robertson; Jongphil Kim; Marina Sehovic; Robert M Wenham; Martine Extermann; Hye Sook Chon
Journal:  Gynecol Oncol       Date:  2021-03-31       Impact factor: 5.482

5.  Ovarian cancer in younger vs older women: a population-based analysis.

Authors:  J K Chan; R Urban; M K Cheung; K Osann; J Y Shin; A Husain; N N Teng; D S Kapp; J S Berek; G S Leiserowitz
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

6.  High grade serous ovarian carcinomas originate in the fallopian tube.

Authors:  S Intidhar Labidi-Galy; Eniko Papp; Dorothy Hallberg; Noushin Niknafs; Vilmos Adleff; Michael Noe; Rohit Bhattacharya; Marian Novak; Siân Jones; Jillian Phallen; Carolyn A Hruban; Michelle S Hirsch; Douglas I Lin; Lauren Schwartz; Cecile L Maire; Jean-Christophe Tille; Michaela Bowden; Ayse Ayhan; Laura D Wood; Robert B Scharpf; Robert Kurman; Tian-Li Wang; Ie-Ming Shih; Rachel Karchin; Ronny Drapkin; Victor E Velculescu
Journal:  Nat Commun       Date:  2017-10-23       Impact factor: 14.919

Review 7.  Biologic Mechanisms Linked to Prognosis in Ovarian Cancer that May Be Affected by Aging.

Authors:  Hye Sook Chon; Marina Sehovic; Douglas Marchion; Christine Walko; Yin Xiong; Martine Extermann
Journal:  J Cancer       Date:  2019-06-02       Impact factor: 4.207

8.  Aging Increases Susceptibility to Ovarian Cancer Metastasis in Murine Allograft Models and Alters Immune Composition of Peritoneal Adipose Tissue.

Authors:  Elizabeth A Loughran; Annemarie K Leonard; Tyvette S Hilliard; Ryan C Phan; Madeleine G Yemc; Elizabeth Harper; Emma Sheedy; Yuliya Klymenko; Marwa Asem; Yueying Liu; Jing Yang; Jeff Johnson; Laura Tarwater; Zonggao Shi; Matthew Leevy; Matthew J Ravosa; M Sharon Stack
Journal:  Neoplasia       Date:  2018-05-10       Impact factor: 5.715

Review 9.  Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments.

Authors:  Lucia Tortorella; Giuseppe Vizzielli; Domenico Fusco; William C Cho; Roberto Bernabei; Giovanni Scambia; Giuseppe Colloca
Journal:  Aging Dis       Date:  2017-10-01       Impact factor: 6.745

10.  Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.

Authors:  Lisa Iversen; Shona Fielding; Øjvind Lidegaard; Lina S Mørch; Charlotte W Skovlund; Philip C Hannaford
Journal:  BMJ       Date:  2018-09-26
View more
  1 in total

Review 1.  The senescence-associated secretory phenotype in ovarian cancer dissemination.

Authors:  Jacob P Veenstra; Lucas Felipe Fernandes Bittencourt; Katherine M Aird
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-18       Impact factor: 5.282

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.